Shijiazhuang Rainbowlabs pharmaceutical Technology Co. Ltd (Rainbowlabs) is a FDA-inspected laboratory set up to provide high quality laboratory testing and services to pharmaceutical companies throughout the world.
Rainbowlabs has received the highest accreditation from the U.S. FDA, Health Canada, ISO and CNAS over the past number of years.With a complete release testing, R&D and cGMP auditing capabilities, we are engaged to continuous improvement of quality management and productivity for the pharmaceutical industry.
We welcome contract testing, R&D and toll manufacture opportunity of APIs and new formulations.
In Dec.2011, Rainbowlabs received ISO9001 & UKAS certificate
In 2012, Rainbowlabs received GSP certificate
In Dec.2011, Rainbowlabs successfully passed the U.S. FDA inspection with Zero 483 and acquired the qualification of third party testing laboratory.
In 2014, Rainbowlabs is approved by Health Canada
In Nov.2014, Rainbowlabs received CNAS certificate
Rainbowlabs also offer offer a QA and regulatory solution including DMF/VMF/EDMF filing, source qualification, cGMP auditing, CAPA, and quality engineering management, supported by our experienced experts in international pharmaceutical industry. We are proud to have obtained a number of successful FDA approvals of our contract API manufacturers since 2009.
In Sep. 2009, we helped through our contract manufacturer of Lincomycin HCl, NCPC Huanluan, in successfully passingthe U.S.FDA audit with Zero 483.
In 2012, we helped through our contract manufacturer of Chongqing South West No.2 Pharmaceutical successfully passing the U.S.FDA inspection.
In Oct. 2012, our on-site QA and regulatory support had helped CSPC Zhongrun to successfully pass the U.S. FDA inspection for Penicillin G Potassium.
In 2013, we helped through our contract manufacturer of Hebei Jianmin successfully passing the U.S.FDA inspection.
In Aug. 2014, our contract manufacturer of Ningxia Tairui successfully passed U.S. FDA inspection for Tylosin Tartrate with our strong support and guidance.